Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy

BACKGROUND: In clinical trials of pegloticase, a PEGylated uricase developed for treatment of gout refractory to conventional therapy, infusion-related reactions (IRs) were the second most frequent adverse event reported. OBJECTIVE: The objective of this study was to provide a detailed account of IR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Rheumatol
Autors principals: Baraf, Herbert S. B., Yood, Robert A., Ottery, Faith D., Sundy, John S., Becker, Michael A.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4280274/
https://ncbi.nlm.nih.gov/pubmed/25417679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/RHU.0000000000000200
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars